JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.
Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".
JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
Related Articles

Industrial: What resources have increased in price since the call for "anti-industrialization"?

Soochow: Lightweight materials break through, optimistic about magnesium alloy, PEEK, PA nylon leading the transformation of humanoid Siasun Robot&Automation.

Guotai Haitong: Policy strengthens insurance asset long-term assessment mechanism, benefiting long-term profit improvement.
Industrial: What resources have increased in price since the call for "anti-industrialization"?

Soochow: Lightweight materials break through, optimistic about magnesium alloy, PEEK, PA nylon leading the transformation of humanoid Siasun Robot&Automation.

Guotai Haitong: Policy strengthens insurance asset long-term assessment mechanism, benefiting long-term profit improvement.
